Xiaogang Guo

Dr. Xiaogang Guo


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2022 in Pharmacological Research
Verified
Journal Article
Closed access
LDLuping Du
Luping Du
XWXuyang Wang
Xuyang Wang
SCSiyuan Chen
Siyuan Chen
XGXiaogang Guo
Xiaogang Guo

19 June 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
TLTianyu Li
Tianyu Li
PWPeizhi Wang
Peizhi Wang
XWXiaozeng Wang
Xiaozeng Wang
ZLZhenyu Liu
Zhenyu Liu
ZZZheng Zhang
Zheng Zhang
JYJinqing Yuan
Jinqing Yuan
Limited evidence exists on the combined and mediating effects of systemic inflammation on the association between insulin resistance and cardiovascular events in patients with diabetes and chronic coronary syndrome (CCS). This secondary analysis of a multicenter prospective cohort included 4419 diabetic CCS patients. Triglyceride–glucose index (TyG) and high-sensitivity C-reactive protein (hsCRP) were applied to evaluate insulin resistance and systemic inflammation, respectively. The primary endpoint was major adverse cardiac event (MACE). Associations of TyG and hsCRP with cardiovascular events were estimated using Cox regression. A mediation analysis was performed to assess whether hsCRP mediates the relationship between TyG and cardiovascular events. Within a median 2.1-year follow-up period, 405 MACEs occurred. Patients with high levels of TyG and hsCRP experienced the highest MACE risk (hazard ratio = 1.82, 95% confidence interval: 1.24–2.70, p = 0.002) compared to individuals with low levels of both markers. HsCRP significantly mediated 14.37% of the relationship between TyG and MACE (p < 0.001). In diabetic CCS patients, insulin resistance and systemic inflammation synergically increased the risk of cardiovascular events, and systemic inflammation partially mediated the association between insulin resistance and clinical outcomes. Combining TyG and hsCRP can help identify high-risk patients. Controlling inflammation in patients with insulin resistance may bring added benefits.

24 August 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MLMiaosen Liu
Miaosen Liu
JLJialan Lv
Jialan Lv
ZPZhicheng Pan
Zhicheng Pan
DWDongfei Wang
Dongfei Wang
LZLiding Zhao
Liding Zhao
XGXiaogang Guo
Xiaogang Guo
The ATP consumption in heart is very intensive to support muscle contraction and relaxation. Mitochondrion is the power plant of the cell. Mitochondrial dysfunction has long been believed as the primary mechanism responsible for the inability of energy generation and utilization in heart failure. In addition, emerging evidence has demonstrated that mitochondrial dysfunction also contributes to calcium dysregulation, oxidative stress, proteotoxic insults and cardiomyocyte death. These elements interact with each other to form a vicious circle in failing heart. The role of mitochondrial dysfunction in the pathogenesis of heart failure has attracted increasing attention. The complex signaling of mitochondrial quality control provides multiple targets for maintaining mitochondrial function. Design of therapeutic strategies targeting mitochondrial dysfunction holds promise for the prevention and treatment of heart failure.

1 July 2020 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
YDYang Dong
Yang Dong
ZPZhicheng Pan
Zhicheng Pan
DWDongfei Wang
Dongfei Wang
JLJialan Lv
Jialan Lv
JFJuan Fang
Juan Fang
XGXiaogang Guo
Xiaogang Guo
Background: Cardiac right ventricular remodeling plays a substantial role in pathogenesis, progression, and prognosis of pulmonary hypertension. Cardiac magnetic resonance is considered an excellent tool for evaluation of right ventricle. However, value of right ventricular remodeling parameters derived from cardiac magnetic resonance in predicting adverse events is controversial. Methods: The Pubmed (MEDLINE), Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure platform (CNKI), China Science and Technology Journal Database (VIP), and Wanfang databases were systematically searched until November 2019. Studies reporting hazard ratios (HRs) for all-cause death and composite end point of pulmonary hypertension were included. Univariate HRs were extracted from the included studies to calculate pooled HRs of each right ventricular remodeling parameter. Results: Eight studies with 1120 patients examining all-cause death (female: 44%–92%, age: 40–67 years old, follow-up time: 27–48 months) and 10 studies with 604 patients examining composite end point (female: 60%–83%, age: 29–57 years old, follow-up time: 10–68 months) met the criteria. Right ventricular ejection fraction was the only parameter which could predict both all-cause death (pooled HR=0.95; P =0.014) and composite end point (pooled HR=0.95; P <0.001), although right ventricular end-diastolic volume index (pooled HR=1.01; P <0.001), right ventricular end-systolic volume index (pooled HR=1.01, P =0.045), and right ventricular mass index (pooled HR=1.03, P =0.032) only predicted composite outcome. Similar results were observed when we conducted the meta-analysis among patients with World Health Organization type I of pulmonary hypertension. Conclusions: Cardiac magnetic resonance–derived right ventricular remodeling parameters have independent prognostic value for all-cause death and composite end point of patients with pulmonary hypertension. Right ventricular ejection fraction was the strongest prognostic factor among all the right ventricular remodeling parameters. Right ventricular mass index, right ventricular end-diastolic volume index, and right ventricular end-systolic volume index also demonstrated prognostic value.

1 February 2022 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
XWXuyang Wang
Xuyang Wang
RWRuilin Wang
Ruilin Wang
LJLiujun Jiang
Liujun Jiang
QXQingbo Xu
Qingbo Xu
XGXiaogang Guo
Xiaogang Guo

19 August 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
DWDongfei Wang
Dongfei Wang
JFJuan Fang
Juan Fang
JLJialan Lv
Jialan Lv
ZPZhicheng Pan
Zhicheng Pan
XYXiang Yin
Xiang Yin
XGXiaogang Guo
Xiaogang Guo
Idiopathic dilated cardiomyopathy (IDCM), characterized by ventricular dilation and impaired systolic function, is a primary cardiomyopathy resulting in heart failure. During heart contraction, the Z ‐line is responsible for transmitting force between sarcomeres and is also a hot spot for muscle cell signalling. Mutations in Z ‐line proteins have been linked to cardiomyopathies in both humans and mice. Actinin‐associated LIM protein (ALP) and enigma homolog protein (ENH), encoded by PDLIM3 and PDLIM5 , are components of the muscle cytoskeleton and localize to the Z ‐line. A PDLIM3 or PDLIM5 deficiency in mice leads to dilated cardiomyopathy. Since PDLIM3 and PDLIM5 are candidate IDCM susceptibility genes, the current study aims to investigate whether polymorphisms within PDLIM3 and PDLIM5 could be correlated with IDCM. We designed a case‐control study, and exons of the PDLIM3 and PDLIM5 were amplified by polymerase chain reactions in 111 IDCM patients and 137 healthy controls. We found that five synonymous polymorphisms had statistical distribution differences between IDCM patients and controls, including rs4861669, rs4862543, c.731 + 131 T > G, c.1789‐3 C > T and rs7690296, according to genotype and allele distribution. Haplotype G‐C‐C‐C and A‐T‐C‐T (rs2306705, rs10866276, rs12644280 and rs4635850 synthesized) were regarded as risk factors for IDCM patients when compared with carriers of other haplotypes (all P < .05). Furthermore, IDCM patients with two novel polymorphisms (c.731 + 131 T > G and c.1789‐3 C > T) had lower systolic blood pressure. In conclusion, these five synonymous polymorphisms might constitute a genetic background that increases the risk of the development of IDCM in the Chinese Han population.